Mendelian randomization of plasma lipidome, inflammatory proteome and heart failure

被引:0
|
作者
Zheng, Zequn [1 ,2 ]
Tan, Xuerui [1 ,2 ]
机构
[1] Shantou Univ, Affiliated Hosp 1, Med Coll, Dept Cardiol, Shantou, Guangdong, Peoples R China
[2] Shantou Univ, Affiliated Hosp 1, Med Coll, Clin Res Ctr, Shantou, Guangdong, Peoples R China
来源
ESC HEART FAILURE | 2024年 / 11卷 / 06期
基金
中国国家自然科学基金;
关键词
causality; heart failure; inflammatory proteome; lipidome; mediator; Mendelian randomization; RISK; INFERENCE;
D O I
10.1002/ehf2.14997
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims Heart failure (HF) is a global health issue, with lipid metabolism and inflammation critically implicated in its progression. This study harnesses cutting-edge, expanded genetic information for lipid and inflammatory protein profiles, employing Mendelian randomization (MR) to uncover genetic risk factors for HF. Methods We assessed genetic susceptibility to HF across 179 lipidomes and 91 inflammatory proteins using instrumental variables (IVs) from recent genome-wide association studies (GWASs) and proteome-wide quantitative trait loci (pQTL) studies. GWASs involving 47 309 HF cases and 930 014 controls were obtained from the Heart Failure Molecular Epidemiology for Therapeutic Targets (HERMES) Consortium. Data on 179 lipids from 7174 individuals in a Finnish cohort and 91 inflammatory proteins from a European pQTL study involving 14 824 individuals are available in the HGRI-EBI catalogue. A two-sample MR approach evaluated the associations, and a two-step mediation analysis explored the mediation role of inflammatory proteins in the lipid-HF pathway. Sensitivity analyses, including MR-RAPS (robust adjusted profile score) and MR-Egger, ensured result robustness. Results Genetic IVs for 162 lipids and 74 inflammatory proteins were successfully identified. MR analysis revealed a genetic association between HF and 31 lipids. Among them, 18 lipids, including sterol ester (27:1/18:0), cholesterol, 9 phosphatidylcholines, phosphatidylinositol (16:0_20:4) and 6 triacylglycerols, were identified as HF risk factors [odds ratio (OR) = 1.037-1.368]. Cholesterol exhibited the most significant association with elevated HF risk [OR = 1.368, 95% confidence interval (CI) = 1.044-1.794, P = 0.023]. In the inflammatory proteome, leukaemia inhibitory factor receptor (OR = 0.841, 95% CI = 0.789-0.897, P = 1.08E-07), fibroblast growth factor 19 (OR = 0.905, 95% CI = 0.830-0.988, P = 0.025) and urokinase-type plasminogen activator (OR = 0.938, 95% CI = 0.886-0.994, P = 0.030) were causally negatively correlated with HF, whereas interleukin-20 receptor subunit alpha (OR = 1.333, 95% CI = 1.094-1.625, P = 0.004) was causally positively correlated with HF. Mediation analysis revealed leukaemia inhibitory factor receptor (mediation proportion: 23.5%-25.2%) and urokinase-type plasminogen activator (mediation proportion: 9.5%-10.7%) as intermediaries in the lipid-inflammation-HF pathway. No evidence of directional horizontal pleiotropy was observed (P > 0.05). Conclusions This study identifies a genetic connection between certain lipids, particularly cholesterol, and HF, highlighting inflammatory proteins that influence HF risk and mediate this relationship, suggesting new therapeutic targets and insights into genetic drivers in HF.
引用
收藏
页码:4209 / 4221
页数:13
相关论文
共 50 条
  • [31] Heart failure and late-onset Alzheimer's disease: A Mendelian randomization study
    Arega, Yibeltal
    Shao, Yongzhao
    FRONTIERS IN GENETICS, 2022, 13
  • [32] Proteome-wide mendelian randomization investigates potential associations in heart failure and its etiology: emphasis on PCSK9
    Lin, Lichao
    Yu, Huizhen
    Xue, Yan
    Wang, Liman
    Zhu, Pengli
    BMC MEDICAL GENOMICS, 2024, 17 (01)
  • [33] Therapeutic Targets for Heart Failure Identified Using Proteomics and Mendelian Randomization
    Henry, Albert
    Gordillo-Maranon, Maria
    Finan, Chris
    Schmidt, Amand F.
    Ferreira, Joao Pedro
    Karra, Ravi
    Sundstrom, Johan
    Lind, Lars
    Arnlov, Johan
    Zannad, Faiez
    Malarstig, Anders
    Hingorani, Aroon D.
    Lumbers, R. Thomas
    CIRCULATION, 2022, 145 (16) : 1205 - 1217
  • [34] The genetic association between hyperthyroidism and heart failure: a Mendelian randomization study
    Liu, Jun
    Wu, Gujie
    Li, Shuqi
    Cheng, Lin
    Ye, Xinping
    FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [35] Role of circulating inflammatory protein in the development of diabetic renal complications: proteome-wide Mendelian randomization and colocalization analyses
    Liu, Wenli
    Zhang, Jiaqi
    Zhang, Duo
    Zhang, Lei
    FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [36] The role of circulating cytokines in heart failure: a bidirectional, two-sample Mendelian randomization study
    Zheng, Haoran
    Mao, Xinxin
    Fu, Zhenyue
    Chen, Chunmei
    Lv, Jiayu
    Wang, Yajiao
    Wang, Yuxin
    Wu, Huaqin
    Li, Yvmeng
    Tan, Yong
    Gao, Xiya
    Zhao, Lu
    Xu, Xia
    Zhang, Bingxuan
    Song, Qingqiao
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2024, 11
  • [37] Plasma metabolome mediates the causal relationship between immune cells and heart failure: a two-step bidirectional Mendelian randomization study
    Li, Tan
    Liu, Yanwei
    Fu, Juncong
    Huang, Langlang
    Liu, Zhongyong
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2024, 11
  • [38] Life-course obesity and heart failure: a two-sample Mendelian randomization study
    Wang, Haili
    Min, Jie
    Zhong, Lei
    Zhang, Jinyu
    Ye, Lili
    Chen, Chunrong
    INTERNAL AND EMERGENCY MEDICINE, 2025, 20 (01) : 171 - 180
  • [39] Gut microbiota and risk of heart failure in European population-A comprehensive Mendelian randomization study
    Huang, Liyan
    Zhao, Xuemei
    Wang, Jing
    Guan, Jingyuan
    Huang, Boping
    Feng, Jiayu
    Li, Xinqing
    Zhang, Yuhui
    Zhang, Jian
    ESC HEART FAILURE, 2025,
  • [40] Causal relationships between uremic metabolites or toxins and heart failure: Univariate and multivariate Mendelian randomization
    Wei, Mingyu
    Hu, Xianjing
    Zhu, Min
    Zhang, Shuai
    Tian, Zhenyu
    Xie, Pengxin
    Cui, Ming
    MEDICINE, 2024, 103 (47)